Ipamorelin
5mg
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist pentapeptide. Research has shown it stimulates growth hormone release without significantly affecting cortisol or prolactin, making it one of the most selective GH secretagogues available. Often paired with CJC-1295 in synergistic research. One of the most studied compounds in endocrinology. Supplied as lyophilised powder, third-party tested, lab certificate published on this page.
Published research on Ipamorelin is indexed on PubMed. See our full UK buyer's guide for Ipamorelin.
Intended Use: Strictly for in-vitro laboratory research. Not for use in humans or animals. Not to be used in foods, drugs, or medical diagnostics. This product has not been evaluated by the MHRA or FDA. Buyer assumes full responsibility for safe handling and regulatory compliance.
98%+
Purity
LAB
Certified
SAME
Day Ship
Quantity
Add £25.01 more for free UK delivery
Damaged or lost? Free reshipment guaranteed
CJC-1295 + Ipamorelin 5+5mg
Pre-blended GHRH + GHRP research peptide vial. CJC-1295 (no DAC) and Ipamorelin combined.
All components in a single lyophilised vial. One reconstitution, one inventory line, one CoA.
Research Use Only
This product is intended strictly for research and laboratory use only. Not for human consumption, medical use, or diagnostic purposes.
Certificate of Analysis
Third-party tested
Lyophilised Stability
24 months
Sealed at -20°C, light-protected
Reconstituted Stability
Up to 3 months
Stored at 2-8°C after mixing
Cold-Chain Shipping
Always
Dry-cold pack, Royal Mail Tracked 24
Important Notice
All compounds are sold individually and do not include research supplies. Products are provided in lyophilised (powder) form and require proper reconstitution before use in research settings.
Related Products
Product Specifications
Research Overview
Ipamorelin is a synthetic pentapeptide and highly selective growth hormone secretagogue (GHS). It acts by mimicking the endogenous hormone ghrelin and binding to the growth hormone secretagogue receptor type 1a (GHS-R1a) in the anterior pituitary gland. Ipamorelin is distinguished from other growth hormone releasing peptides (GHRPs) such as GHRP-2 and GHRP-6 by its exceptional selectivity, it stimulates growth hormone release without significantly elevating cortisol, prolactin, or adrenocorticotropic hormone (ACTH) levels. This selectivity makes Ipamorelin the most specific GHS available for endocrine research, minimising confounding hormonal variables in experimental designs. Early clinical research by Novo Nordisk investigated Ipamorelin as a potential treatment for postoperative ileus, examining its effects on gastrointestinal motility in addition to GH secretion. In current research practice, Ipamorelin is frequently studied in combination with CJC-1295 (modified GRF 1-29) for synergistic growth hormone secretion, Ipamorelin acting at the GHS receptor and CJC-1295 acting at the GHRH receptor to produce amplified pulsatile GH release through complementary receptor pathways.
Product Specifications
Laboratory Handling
- Store lyophilised vials at -20°C. Reconstituted Ipamorelin should be refrigerated at 2-8°C and used within 4 weeks.
- Reconstitute with bacteriostatic water. Direct the stream of water down the side of the vial and swirl gently.
- Handle under aseptic conditions using sterile syringes. Wipe vial stopper with an alcohol swab before each use.
- Avoid repeated freeze-thaw cycles. Prepare single-use aliquots where possible to maintain peptide integrity.
Frequently Asked Questions
Ipamorelin
5mg · £19.99